{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:19:24Z","timestamp":1780391964768,"version":"3.54.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03364-z","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T22:26:14Z","timestamp":1772835974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating Dextrose-Derived Interference in Low-Concentration Monoclonal Antibody Quantification for Clinical In-Use Studies"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4192-0412","authenticated-orcid":false,"given":"Rakesh","family":"Dachineni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0714-1247","authenticated-orcid":false,"given":"Nida","family":"Naseer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2454-022X","authenticated-orcid":false,"given":"Zaneta","family":"Maijorovaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2748-0026","authenticated-orcid":false,"given":"Haichen","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"issue":"9","key":"3364_CR1","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.xphs.2023.05.002","volume":"112","author":"M Bl\u00fcmel","year":"2023","unstructured":"Bl\u00fcmel M, Liu J, de Jong I, Weiser S, Fast J, Litowski J, et al. Current industry best practice on in-use stability and compatibility studies for biological products. J Pharm Sci. 2023;112(9):2332\u201346.","journal-title":"J Pharm Sci"},{"issue":"4","key":"3364_CR2","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.xphs.2021.09.043","volume":"111","author":"DE Kamen","year":"2022","unstructured":"Kamen DE, Crotts G, Narasimhan C, Hu Q, Bhargava AC, Muthurania K, et al. An intercompany perspective on compatibility and in-use stability studies to enable administration of biopharmaceutical drug products. J Pharm Sci. 2022;111(4):1092\u2013103.","journal-title":"J Pharm Sci"},{"issue":"15","key":"3364_CR3","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.cell.2022.05.029","volume":"185","author":"PJ Carter","year":"2022","unstructured":"Carter PJ, Rajpal A. Designing antibodies as therapeutics. Cell. 2022;185(15):2789\u2013805.","journal-title":"Cell"},{"issue":"3","key":"3364_CR4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/cpt.3150","volume":"115","author":"JD Davis","year":"2024","unstructured":"Davis JD, Bravo Padros M, Conrado DJ, Ganguly S, Guan X, Hassan HE, et al. Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development. Clin Pharmacol Ther. 2024;115(3):422\u201339.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3364_CR5","doi-asserted-by":"crossref","first-page":"1685814","DOI":"10.1080\/19420862.2019.1685814","volume":"12","author":"S Luo","year":"2020","unstructured":"Luo S, McSweeney KM, Wang T, Bacot SM, Feldman GM, Zhang B. Defining the right diluent for intravenous infusion of therapeutic antibodies. MAbs. 2020;12(1):1685814.","journal-title":"MAbs"},{"key":"3364_CR6","unstructured":"Immunocore. KIMMTRAK. Prescribing Information. United Kingdom, OX144RY11\/2022. Available from: https:\/\/d1io3yog0oux5.cloudfront.net\/_f594b2acb40fb5e6ac99c2f7cf8cc3f4\/immunocore\/files\/documents\/Approved_USPI_11_20_22_for_commercial_printing_and_website.pdf. Accessed 12 Aug 2024."},{"key":"3364_CR7","unstructured":"Amgen. BLINCYTO. Prescribing Information. Thousand Oaks, CA 9132006\/2024. from: https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/piamgen-com\/blincyto\/blincyto_pi_hcp_english.pdf. Accessed 13 Aug 2024."},{"key":"3364_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-025-03949-6","author":"P Sharma","year":"2025","unstructured":"Sharma P, Nie H. Spotlight on clinical in-use parameters for intravenous infusion of therapeutic antibodies: a systematic review. Pharm Res. 2025. https:\/\/doi.org\/10.1007\/s11095-025-03949-6.","journal-title":"Pharm Res"},{"issue":"4","key":"3364_CR9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/1087057114557781","volume":"20","author":"A Niedziela-Majka","year":"2015","unstructured":"Niedziela-Majka A, Kan E, Weissburg P, Mehra U, Sellers S, Sakowicz R. High-throughput screening of formulations to optimize the thermal stability of a therapeutic monoclonal antibody. SLAS Discov. 2015;20(4):552\u20139.","journal-title":"SLAS Discov"},{"key":"3364_CR10","doi-asserted-by":"crossref","first-page":"1257665","DOI":"10.3389\/fbioe.2023.1257665","volume":"11","author":"Q Wu","year":"2023","unstructured":"Wu Q, Cao C, Wei S, He H, Chen K, Su L, et al. Decreasing hydrophobicity or shielding hydrophobic areas of CH2 attenuates low pH-induced IgG4 aggregation. Front Bioeng Biotechnol. 2023;11:1257665.","journal-title":"Front Bioeng Biotechnol"},{"issue":"4","key":"3364_CR11","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.xphs.2020.10.036","volume":"110","author":"A Kannan","year":"2021","unstructured":"Kannan A, Shieh IC, Hristov P, Fuller GG. In-use interfacial stability of monoclonal antibody formulations diluted in saline iv bags. J Pharm Sci. 2021;110(4):1687\u201392.","journal-title":"J Pharm Sci"},{"key":"3364_CR12","doi-asserted-by":"crossref","unstructured":"Arvinte T, Palais C, Green-Trexler E, Gregory S, Mach H, Narasimhan C,\u00a0& Shameem, M. editors. Aggregation of biopharmaceuticals in human plasma and human serum: implications for drug research and development. MAbs. 2013;5(3):491\u2013500. Taylor & Francis.","DOI":"10.4161\/mabs.24245"},{"key":"3364_CR13","unstructured":"Genentech. Avastin. In: Prescribing information. South San Francisco, CA 94080. 2022. Available from: https:\/\/www.gene.com\/download\/pdf\/avastin_prescribing.pdf. Accessed 13 Aug 2024."},{"key":"3364_CR14","unstructured":"Genentech. Perjeta. In: Prescribing information. South San Francisco, CA 94080. 2021. Available from: https:\/\/www.gene.com\/download\/pdf\/perjeta_prescribing.pdf. Accessed 13 Aug 2024."},{"key":"3364_CR15","unstructured":"Eli Lilly and Company. Cyramza. In: Prescribing information. Indianapolis, IN 46285. 2022. Available from: https:\/\/uspl.lilly.com\/cyramza\/cyramza.html#pi. Accessed 13 Aug 2024."},{"key":"3364_CR16","unstructured":"Eli Lilly and Company. Portrazza. In: Prescribing information. Indianapolis, IN 46285. 2015. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125547s000lbl.pdf. Accessed 13 Aug 2024."},{"key":"3364_CR17","unstructured":"Eli Lilly and Company. Lartruvo. In: Prescribing information. Indianapolis, IN 46285. 2016. Available from\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761038lbl.pdf. Accessed 13 Aug 2024."},{"key":"3364_CR18","unstructured":"MacroGenics. Margenza. In: Prescribing information. Rockville, MD 20850. 2023. Available from: https:\/\/www.margenza.com\/pdf\/prescribing-information.pdf. Accessed 12 Aug 2024"},{"issue":"1","key":"3364_CR19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejpb.2008.04.021","volume":"70","author":"S Fischer","year":"2008","unstructured":"Fischer S, Hoernschemeyer J, Mahler H-C. Glycation during storage and administration of monoclonal antibody formulations. Eur J Pharm Biopharm. 2008;70(1):42\u201350.","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"3364_CR20","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2337\/diacare.28.4.981","volume":"28","author":"BJ Krajicek","year":"2005","unstructured":"Krajicek BJ, Kudva YC, Hurley HA. Potentially important contribution of dextrose used as diluent to hyperglycemia in hospitalized patients. Diabetes Care. 2005;28(4):981\u20132.","journal-title":"Diabetes Care"},{"issue":"6","key":"3364_CR21","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/19420862.2015.1087636","volume":"7","author":"S Luo","year":"2015","unstructured":"Luo S, Zhang B. Dextrose-mediated aggregation of therapeutic monoclonal antibodies in human plasma: implication of isoelectric precipitation of complement proteins. MAbs. 2015;7(6):1094\u2013103.","journal-title":"MAbs"},{"issue":"1","key":"3364_CR22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12296-5","volume":"7","author":"J Haybrard","year":"2017","unstructured":"Haybrard J, Simon N, Danel C, Pin\u00e7on C, Barth\u00e9l\u00e9my C, Tessier FJ, et al. Factors generating glucose degradation products in sterile glucose solutions for infusion: statistical relevance determination of their impacts. Sci Rep. 2017;7(1): 11932.","journal-title":"Sci Rep"},{"issue":"4","key":"3364_CR23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2478\/v10222-012-0082-4","volume":"63","author":"S Kowalski","year":"2013","unstructured":"Kowalski S, Lukasiewicz M, Duda-Chodak A, Zi\u0119\u0107 G. 5-Hydroxymethyl-2-furfural (HMF)\u2013heat-induced formation, occurrence in food and biotransformation-a review. Pol J Food Nutr Sci. 2013;63(4):207\u201325.","journal-title":"Pol J Food Nutr Sci"},{"key":"3364_CR24","unstructured":"STERILE DRUG PROCESS INSPECTIONS. FOOD AND DRUG ADMINISTRATION COMPLIANCEPROGRAM GUIDANCE MANUAL, Program 7356.002A. https:\/\/www.fda.gov\/media\/75174\/download. Accessed 17 Jun 2025."},{"issue":"1","key":"3364_CR25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10047-006-0358-8","volume":"10","author":"T Tomo","year":"2007","unstructured":"Tomo T, Okabe E, Yamamoto T, Namoto S, Iwashita T, Matsuyama K, et al. Impact of 3,4-dideoxyglucosone-3-ene (3,4-DGE) on cytotoxicity of acidic heat-sterilized peritoneal dialysis fluid. J Artif Organs. 2007;10(1):47\u201351.","journal-title":"J Artif Organs"},{"issue":"8","key":"3364_CR26","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/bmc.1194","volume":"23","author":"M Frischmann","year":"2009","unstructured":"Frischmann M, Spitzer J, F\u00fcnfrocken M, Mittelmaier S, Deckert M, Fichert T, et al. Development and validation of an HPLC method to quantify 3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids. Biomed Chromatogr. 2009;23(8):843\u201351.","journal-title":"Biomed Chromatogr"},{"issue":"2","key":"3364_CR27","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1046\/j.1523-1755.2002.00490.x","volume":"62","author":"T Linden","year":"2002","unstructured":"Linden T, Cohen A, Deppisch R, Kjellstrand P, Wieslander A. 3,4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int. 2002;62(2):697\u2013703.","journal-title":"Kidney Int"},{"issue":"1","key":"3364_CR28","first-page":"17","volume":"7","author":"CT Hung","year":"1982","unstructured":"Hung CT, Selkirk AB, Taylor RB. A chromatographic quality control procedure based on HPLC for 5-hydroxymethylfurfural in autoclaved D-glucose infusion fluids. J Clin Hosp Pharm. 1982;7(1):17\u201323.","journal-title":"J Clin Hosp Pharm"},{"issue":"2","key":"3364_CR29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0021-9673(01)93992-5","volume":"467","author":"AP Cook","year":"1989","unstructured":"Cook AP, Macleod TM, Appleton JD, Fell AF. Reversed-phase high-performance liquid chromatographic method for the quantification of 5-hydroxymethylfurfural as the major degradation product of glucose in infusion fluids. J Chromatogr. 1989;467(2):395\u2013401.","journal-title":"J Chromatogr"},{"key":"3364_CR30","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.toxrep.2020.10.010","volume":"7","author":"E Li","year":"2020","unstructured":"Li E, Lin N, Hao R, Fan X, Lin L, Hu G, et al. 5-HMF induces anaphylactoid reactions in vivo and in vitro. Toxicol Rep. 2020;7:1402\u201311.","journal-title":"Toxicol Rep"},{"issue":"7","key":"3364_CR31","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00134-010-1873-x","volume":"36","author":"A Bryland","year":"2010","unstructured":"Bryland A, Broman M, Erixon M, Klarin B, Lind\u00e9n T, Friberg H, et al. Infusion fluids contain harmful glucose degradation products. Intensive Care Med. 2010;36(7):1213\u201320.","journal-title":"Intensive Care Med"},{"key":"3364_CR32","unstructured":"United States Pharmacopeia (USP) NFN, and Pharmacopeial Forum (PF). Dextrose Injection Monograph. Pharmacopeial Forum: volume no 46(3). https:\/\/online.uspnf.com\/: USP-NF\/PF; 2022.\u00a0Accessed 22 Oct 2025."},{"key":"3364_CR33","doi-asserted-by":"crossref","first-page":"123926","DOI":"10.1016\/j.ijpharm.2024.123926","volume":"654","author":"E De Diana","year":"2024","unstructured":"De Diana E, Rizzotto E, Inciardi I, Menilli L, Coppola M, de Laureto PP, et al. Towards a better understanding of light-glucose induced modifications on the structure and biological activity of formulated Nivolumab. Int J Pharm. 2024;654:123926.","journal-title":"Int J Pharm"},{"key":"3364_CR34","doi-asserted-by":"crossref","unstructured":"Simonian MH. Spectrophotometric determination of protein concentration. Curr Protoc Cell Biol. 2002; Appendix 3:Appendix 3B.","DOI":"10.1002\/0471143030.cba03bs15"},{"issue":"15","key":"3364_CR35","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1007\/s00216-022-03910-1","volume":"414","author":"K Reinmuth-Selzle","year":"2022","unstructured":"Reinmuth-Selzle K, Tchipilov T, Backes AT, Tscheuschner G, Tang K, Ziegler K, et al. Determination of the protein content of complex samples by aromatic amino acid analysis, liquid chromatography-UV absorbance, and colorimetry. Anal Bioanal Chem. 2022;414(15):4457\u201370.","journal-title":"Anal Bioanal Chem"},{"issue":"1","key":"3364_CR36","doi-asserted-by":"crossref","first-page":"3.1","DOI":"10.1002\/0471140864.ps0301s33","volume":"33","author":"GR Grimsley","year":"2003","unstructured":"Grimsley GR, Pace CN. Spectrophotometric Determination of Protein Concentration. Curr Protoc Protein Sci. 2003;33(1):3.1-3.1.9.","journal-title":"Curr Protoc Protein Sci"},{"key":"3364_CR37","unstructured":"C Technologies, INC. Variable Pathlength Slope Spectroscopy. DOC0084 SoloVPE Abstract II Rev.01, 2018. https:\/\/ctech.repligen.com\/wp-content\/uploads\/2021\/03\/The-SoloVPE-System-Features-and-Benefits-Overview.pdf. Accessed 18 Mar 2025."},{"key":"3364_CR38","unstructured":"Repligen. CTech SoloVPE PLUS System 2025. Available from: https:\/\/www.repligen.com\/solovpe#:~:text=0.01%20mg\/mL%20to%20300%20mg\/mL%20without%20dilution. Accessed 08 Mar 2025."},{"key":"3364_CR39","unstructured":"A theoretical and practical guide for spectrophotometric determination of protein concentrations at 280 nm. https:\/\/documents.thermofisher.com\/TFS-Assets\/BID\/Technical-Notes\/spectrophotometric-determination-protein-concentrations-280nm-technote.pdf. Accessed 18 MAR 2025."},{"issue":"3","key":"3364_CR40","first-page":"6801","volume":"11","author":"Y Liu","year":"2016","unstructured":"Liu Y, Li H, Yang J, Li B, Zhang C, Liu M. An improved method for determination of pentosans in pulps using dual-wavelength spectroscopy. Bioresources. 2016;11(3):6801\u20137.","journal-title":"Bioresources."},{"issue":"7","key":"3364_CR41","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1021\/acs.molpharmaceut.5b00162","volume":"12","author":"H Nie","year":"2015","unstructured":"Nie H, Mo H, Zhang M, Song Y, Fang K, Taylor LS, et al. Investigating the interaction pattern and structural elements of a drug\u2013polymer complex at the molecular level. Mol Pharm. 2015;12(7):2459\u201368.","journal-title":"Mol Pharm"},{"key":"3364_CR42","doi-asserted-by":"publisher","unstructured":"Dachineni R, Nie H. Navigating the use of 2-hydroxypropyl-\u03b2-cyclodextrin in liquid formulations: a systematic study of physical properties and surfactant compatibility. Int J Pharm. 2026;689:126498.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2025.126498","DOI":"10.1016\/j.ijpharm.2025.126498"},{"key":"3364_CR43","doi-asserted-by":"crossref","first-page":"121608","DOI":"10.1016\/j.ijpharm.2022.121608","volume":"617","author":"H Nie","year":"2022","unstructured":"Nie H, Klinzing G, Xu W. A comparative study of applying backscattering and transmission Raman spectroscopy to quantify solid-state form conversion in pharmaceutical tablets. Int J Pharm. 2022;617:121608.","journal-title":"Int J Pharm"},{"issue":"11","key":"3364_CR44","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1021\/acs.molpharmaceut.6b00740","volume":"13","author":"H Nie","year":"2016","unstructured":"Nie H, Su Y, Zhang M, Song Y, Leone A, Taylor LS, et al. Solid-state spectroscopic investigation of molecular interactions between clofazimine and hypromellose phthalate in amorphous solid dispersions. Mol Pharm. 2016;13(11):3964\u201375.","journal-title":"Mol Pharm"},{"key":"3364_CR45","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jpba.2015.10.024","volume":"118","author":"H Nie","year":"2016","unstructured":"Nie H, Liu Z, Marks BC, Taylor LS, Byrn SR, Marsac PJ. Analytical approaches to investigate salt disproportionation in tablet matrices by Raman spectroscopy and Raman mapping. J Pharm Biomed Anal. 2016;118:328\u201337.","journal-title":"J Pharm Biomed Anal"},{"issue":"11","key":"3364_CR46","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1021\/acs.molpharmaceut.3c00628","volume":"20","author":"Z Chen","year":"2023","unstructured":"Chen Z, Nie H, Benmore CJ, Smith PA, Du Y, Byrn S, et al. Probing molecular packing of amorphous pharmaceutical solids using x-ray atomic pair distribution function and solid-state NMR. Mol Pharm. 2023;20(11):5763\u201377.","journal-title":"Mol Pharm"},{"key":"3364_CR47","doi-asserted-by":"crossref","unstructured":"LV P, HU L, Yeh J, Gao X, Liu D, Wang G, et al. Development of an in vitro potency assay system for quality control of anti-human epidermal growth factor receptor 2 antibody admixtures. Indian J Pharm Sci. 2021;83(2):293.","DOI":"10.36468\/pharmaceutical-sciences.775"},{"issue":"1","key":"3364_CR48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/biomedicines13010023","volume":"13","author":"P Bharali","year":"2024","unstructured":"Bharali P, Chand S, Chander H. A Cost-Effective and Robust Cell-Based Bioassay Method for Evaluating the Bioactivity of Trastuzumab-like Antibodies. Biomedicines. 2024;13(1):23.","journal-title":"Biomedicines"},{"key":"3364_CR49","doi-asserted-by":"publisher","unstructured":"\u017digon-Branc S, Barli\u010d A, Jeras M. In vitro Cell-Based Assays for Potency Testing of Anti-TNF-\u03b1 Biological Drugs. Cytokines: IntechOpen; 2019. https:\/\/doi.org\/10.5772\/intechopen.85237","DOI":"10.5772\/intechopen.85237"},{"key":"3364_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16101310","author":"A Boianelli","year":"2024","unstructured":"Boianelli A, Nordell P, Earl J, Naylor J, Hornigold D, Jansson L\u00f6fmark R, et al. Establishing a relationship between in vitro potency in cell-based assays and clinical efficacious concentrations for approved GLP-1 receptor agonists. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16101310.","journal-title":"Pharmaceutics"},{"key":"3364_CR51","first-page":"55376","volume":"127","author":"L Tierrablanca-S\u00e1nchez","year":"2017","unstructured":"Tierrablanca-S\u00e1nchez L, Mart\u00ednez VPM, Iba\u00f1ez NDR, Ram\u00edrez NOP, Ortiz FLF, Medina-Rivero E. Determination of the relative potency of an anti-TNF monoclonal antibody (mAb) by neutralizing TNF using an in vitro bioanalytical method. Journal of Visualized Experiments: JoVE. 2017;127:55376.","journal-title":"Journal of Visualized Experiments: JoVE"},{"issue":"4","key":"3364_CR52","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1080\/19420862.2015.1046664","volume":"7","author":"S Morar-Mitrica","year":"2015","unstructured":"Morar-Mitrica S, Puri M, Beumer Sassi A, Fuller J, Hu P, Crotts G, et al. Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration. MAbs. 2015;7(4):792\u2013803.","journal-title":"MAbs"},{"issue":"4","key":"3364_CR53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/chemengineering5040084","volume":"5","author":"VA Poluektova","year":"2021","unstructured":"Poluektova VA, Cherkashina NI, Starchenko SA, Romanyuk DS. Features of the chemical interaction of 2-furaldehyde and 1,3,5-trihydroxybenzene in an alkaline medium to obtain a plasticizing additive. ChemEngineering. 2021;5(4):84.","journal-title":"ChemEngineering"},{"key":"3364_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ph14111121","author":"S Leitzen","year":"2021","unstructured":"Leitzen S, Vogel M, Steffens M, Zapf T, M\u00fcller CE, Brandl M. Quantification of degradation products formed during heat sterilization of glucose solutions by LC-MS\/MS: impact of autoclaving temperature and duration on degradation. Pharmaceuticals (Basel). 2021. https:\/\/doi.org\/10.3390\/ph14111121.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"3364_CR55","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/089686080402400415","volume":"24","author":"P Kjellstrand","year":"2004","unstructured":"Kjellstrand P, Erixon M, Wieslander A, Lind\u00e9n T, Martinson E. Temperature: the single most important factor for degradation of glucose fluids during storage. Perit Dial Int. 2004;24(4):385\u201391.","journal-title":"Perit Dial Int"},{"issue":"2","key":"3364_CR56","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/ndt\/gfad153","volume":"39","author":"JHC Chen","year":"2024","unstructured":"Chen JHC, Johnson DW, Cho Y, Cheetham M, Sud K, Hayat A, et al. Associations of neutral pH, low-GDP peritoneal dialysis solutions with patient survival, transfer to haemodialysis and peritonitis. Nephrol Dial Transplant. 2024;39(2):222\u201332.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"3364_CR57","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3390\/ph14111121","volume":"14","author":"S Leitzen","year":"2021","unstructured":"Leitzen S, Vogel M, Steffens M, Zapf T, M\u00fcller CE, Brandl M. Quantification of degradation products formed during heat sterilization of glucose solutions by LC-MS\/MS: impact of autoclaving temperature and duration on degradation. Pharmaceuticals. 2021;14(11):1121.","journal-title":"Pharmaceuticals"},{"key":"3364_CR58","unstructured":"Agalloco J. Loaded Chamber Temperature Distribution Studies: Pharma Manufacturing 2018 [Available from: https:\/\/www.pharmamanufacturing.com\/home\/article\/11305144\/loaded-chamber-temperature-distribution-studies.\u00a0Accessed 14 Mar 2025."},{"key":"3364_CR59","doi-asserted-by":"crossref","unstructured":"Christopoulos TK, Diamandis EP. 10 - Immunoassay Configurations. In: Diamandis EP, Christopoulos TK, editors. Immunoassay. San Diego: Academic Press; 1996. p. 227\u201336.","DOI":"10.1016\/B978-012214730-2\/50011-X"},{"issue":"D1","key":"3364_CR60","doi-asserted-by":"crossref","first-page":"D1535","DOI":"10.1093\/nar\/gkab944","volume":"50","author":"LP Kozlowski","year":"2022","unstructured":"Kozlowski LP. Proteome-pI 2.0: proteome isoelectric point database update. Nucleic Acids Res. 2022;50(D1):D1535\u201340.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"3364_CR61","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/19420862.2018.1438795","volume":"10","author":"D Boyd","year":"2018","unstructured":"Boyd D, Ebrahimi A, Ronan S, Mickus B, Schenauer M, Wang J, et al. Isolation and characterization of a monoclonal antibody containing an extra heavy-light chain Fab arm. MAbs. 2018;10(3):346\u201353.","journal-title":"MAbs"},{"issue":"1","key":"3364_CR62","volume":"12","author":"ZD Dunn","year":"2020","unstructured":"Dunn ZD, Desai J, Leme GM, Stoll DR, Richardson DD. Rapid two-dimensional Protein-A size exclusion chromatography of monoclonal antibodies for titer and aggregation measurements from harvested cell culture fluid samples. MAbs. 2020;12(1): 1702263.","journal-title":"MAbs"},{"issue":"5","key":"3364_CR63","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4161\/mabs.2.5.12645","volume":"2","author":"HF Liu","year":"2010","unstructured":"Liu HF, Ma J, Winter C, Bayer R. Recovery and purification process development for monoclonal antibody production. MAbs. 2010;2(5):480\u201399.","journal-title":"MAbs"},{"issue":"9","key":"3364_CR64","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/jssc.201800963","volume":"42","author":"AM Ramos-de-la-Pe\u00f1a","year":"2019","unstructured":"Ramos-de-la-Pe\u00f1a AM, Gonz\u00e1lez-Valdez J, Aguilar O. Protein A chromatography: challenges and progress in the purification of monoclonal antibodies. J Sep Sci. 2019;42(9):1816\u201327.","journal-title":"J Sep Sci"},{"issue":"3","key":"3364_CR65","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-3083.1982.tb00649.x","volume":"15","author":"E Van Loghem","year":"1982","unstructured":"Van Loghem E, Frangione B, Recht B, Franklin E. Staphylococcal protein A and human IgG subclasses and allotypes. Scand J Immunol. 1982;15(3):275\u20138.","journal-title":"Scand J Immunol"},{"key":"3364_CR66","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jchromb.2014.05.029","volume":"962","author":"P Leblebici","year":"2014","unstructured":"Leblebici P, Leblebici ME, Ferreira-da-Silva F, Rodrigues AE, Pais LS. Separation of human immunoglobulin G subclasses on a protein A monolith column. J Chromatogr B. 2014;962:89\u201393.","journal-title":"J Chromatogr B"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03364-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03364-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03364-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:51:22Z","timestamp":1780390282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03364-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":66,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["3364"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03364-z","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.\u00a0All authors are employees of Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"133"}}